Neurogene Inc (NASDAQ: NGNE) has experienced a rise in its stock price by 15.83 compared to its previous closing price of 17.75. However, the company has seen a gain of 20.30% in its stock price over the last five trading days. businesswire.com reported 2025-05-16 that NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic e.
Is It Worth Investing in Neurogene Inc (NASDAQ: NGNE) Right Now?
Company’s 36-month beta value is 1.55.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NGNE is 11.75M, and currently, short sellers hold a 22.95% ratio of that floaft. The average trading volume of NGNE on June 04, 2025 was 269.74K shares.
NGNE’s Market Performance
NGNE’s stock has seen a 20.30% increase for the week, with a 21.15% rise in the past month and a 25.75% gain in the past quarter. The volatility ratio for the week is 10.09%, and the volatility levels for the past 30 days are at 10.13% for Neurogene Inc The simple moving average for the past 20 days is 20.19% for NGNE’s stock, with a -21.92% simple moving average for the past 200 days.
Analysts’ Opinion of NGNE
Many brokerage firms have already submitted their reports for NGNE stocks, with Robert W. Baird repeating the rating for NGNE by listing it as a “Neutral.” The predicted price for NGNE in the upcoming period, according to Robert W. Baird is $24 based on the research report published on May 16, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see NGNE reach a price target of $65. The rating they have provided for NGNE stocks is “Outperform” according to the report published on June 27th, 2024.
Robert W. Baird gave a rating of “Outperform” to NGNE, setting the target price at $54 in the report published on June 11th of the previous year.
NGNE Trading at 43.31% from the 50-Day Moving Average
After a stumble in the market that brought NGNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.40% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NGNE starting from Cobb Stuart, who sale 6,797 shares at the price of $15.15 back on May 14 ’25. After this action, Cobb Stuart now owns 20,794 shares of Neurogene Inc, valued at $103,003 using the latest closing price.
STUART COBB, the Officer of Neurogene Inc, proposed sale 6,797 shares at $15.51 during a trade that took place back on May 14 ’25, which means that STUART COBB is holding shares at $105,421 based on the most recent closing price.
Stock Fundamentals for NGNE
Current profitability levels for the company are sitting at:
- -97.02 for the present operating margin
- -16.02 for the gross margin
The net margin for Neurogene Inc stands at -87.43. The total capital return value is set at -0.3. Equity return is now at value -34.97, with -31.67 for asset returns.
Based on Neurogene Inc (NGNE), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -5.15. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -8158.64.
Currently, EBITDA for the company is -71.89 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of 255.14. The receivables turnover for the company is 1.55for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.03.
Conclusion
In a nutshell, Neurogene Inc (NGNE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
